CARA News and Press, Cara Therapeutics Inc. From 12/22/21

The Premium Portfolio has gained +6.80% YTD compared to the S&P 500 +21.62% YTD and the Aurum Hedge Fund Industry Index +6.31% with one week to go. The Premium Portfolio compound annual growth rate (CAGR) of +25.57% compares favorably to the S&P 500 of +14.31% CAGR from 2018. ...

Cara Therapeutics (NASDAQ:CARA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) greenlighted a form of reimbursement for KORSUVA (difelikefalin) injection in the anti-pruritic functional category. The Transitional Drug Add-On Payment Adjustment (TDAPA) issued for KO...

KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 STAMFORD, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medicare & M...

SWK Holdings (NASDAQ:SWKH) wholly-owned subsidiary, Enteris BioPharma received a $5M milestone payment from Cara Therapeutics (NASDAQ:CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA. Enteris is entitled to retain $3M of t...

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid...

STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...

Cara Therapeutics, Inc. (CARA) Q3 2021 Earnings Conference Call November 08, 2021 4:30 PM ET Company Participants William Gramig - Stern Investor Relations Derek Chalmers - President and Chief Executive Officer Christopher Posner - Incoming CEO Thomas Reilly - Chief Financial Officer Conferen...

Cara Therapeutics (NASDAQ:CARA) shares rose more than 10% post market after the company reported third-quarter earnings that beat Wall Street estimates and provided an update on its cash position. Quarterly revenue more than doubled to $20.27M, beating analysts' average estimat...

Cara Therapeutics (NASDAQ:CARA): Q3 GAAP EPS of -$0.02 beats by $0.40. Revenue of $20.27M (+118.7% Y/Y) beats by $9.06M. Press Release Cash, cash equivalents and marketable securities at September 30, 2021 totaled $193.4 million compared to $251.5 million at December 31, 2020.  Financial...

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) – – Christopher Posner Appointed Presiden...